COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review

Overview

Journal Pathog Immun

Date 2021 May 31

PMID 34056149

Citations 37

Authors

Jessica M Jones

Aiman J Faruqi

James K Sullivan

Cassandra Calabrese

Leonard H Calabrese

Affiliations

Soon will be listed here.

Abstract

Background: The role of humoral immunity has been well established in reducing infection risk and facilitating viral clearance in patients with COVID-19. However, the relationship between specific antibody responses and severity of COVID-19 is less well understood.

Methods: To address this question and identify gaps in knowledge, we utilized the methodology of a scoping review to interrogate risk of infection and clinical outcomes of COVID-19 in patients with iatrogenic and inborn humoral immunodeficiency states based on existing literature.

Results: Among patients with iatrogenic B-cell depletion, particularly with agents targeting CD20, our analysis found increased risk of severe COVID-19 and death across a range of underlying disease states. Among patients with humoral inborn errors of immunity with COVID-19, our synthesis found that patients with dysregulated humoral immunity, predominantly common variable immunodeficiency (CVID), may be more susceptible to severe COVID-19 than patients with humoral immunodeficiency states due to X-linked agammaglobulinemia and other miscellaneous forms of humoral immunodeficiency. There were insufficient data to appraise the risk of COVID-19 infection in both populations of patients.

Conclusions: Our work identifies potentially significant predictors of COVID-19 severity in patients with humoral immunodeficiency states and highlights the need for larger studies to control for clinical and biologic confounders of disease severity.

Citing Articles

Patients with systemic autoimmune rheumatic diseases remain at risk for hospitalisation for COVID-19 infection in the Omicron era (2022-2024): a retrospective cohort study.

Patel N, Srivatsan S, Kowalski E, King A, Wang X, Vanni K RMD Open. 2025; 11(1).

PMID: 40044572 PMC: 11883534. DOI: 10.1136/rmdopen-2024-005114.

Exploring the Relationship Between Humoral and Cellular T Cell Responses Against SARS-CoV-2 in Exposed Individuals From Emilia Romagna Region and COVID-19 Severity.

Mazzotti L, Borges de Souza P, Azzali I, Angeli D, Nanni O, Sambri V HLA. 2025; 105(1):e70011.

PMID: 39807702 PMC: 11731316. DOI: 10.1111/tan.70011.

Prolonged SARS-CoV-2 Viremia in an Immunocompromised Patient.

Abdulrasak M, Hootak S J Med Cases. 2025; 16(1):6-10.

PMID: 39759167 PMC: 11699861. DOI: 10.14740/jmc5064.

COVID-19 Pneumonia Diagnosed by Bronchoalveolar Lavage Fluid, With CD4 T-cell Depletion Contributing to Prolonged Infection: Two Case Reports.

Tsukida S, Hongo M, Akasaki K, Sone T, Nishi K Cureus. 2024; 16(11):e74380.

PMID: 39723265 PMC: 11669300. DOI: 10.7759/cureus.74380.

Sequelae of B-Cell Depleting Therapy: An Immunologist's Perspective.

Kacar M, Al-Hakim A, Savic S BioDrugs. 2024; 39(1):103-130.

PMID: 39680306 DOI: 10.1007/s40259-024-00696-9.

References

Gudbjartsson D, Norddahl G, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E . Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med. 2020; 383(18):1724-1734. PMC: 7494247. DOI: 10.1056/NEJMoa2026116. View

Martinot M, Jary A, Fafi-Kremer S, Leducq V, Delagreverie H, Garnier M . Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019. Clin Infect Dis. 2020; 73(7):e1762-e1765. PMC: 7543308. DOI: 10.1093/cid/ciaa1474. View

Moore J, Ganapathiraju P, Kurtz C, Wainscoat B . A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma. Am J Case Rep. 2020; 21:e927812. PMC: 7542548. DOI: 10.12659/AJCR.927812. View

Angeletti A, Drovandi S, Sanguineri F, Santaniello M, Ferrando G, Forno R . COVID-19 in Children with Nephrotic Syndrome on Anti-CD20 Chronic Immunosuppression. Clin J Am Soc Nephrol. 2020; 15(10):1494-1495. PMC: 7536764. DOI: 10.2215/CJN.06400420. View

Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, Maria A . Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. Ann Rheum Dis. 2020; 80(1):e10. DOI: 10.1136/annrheumdis-2020-217549. View

Anderson E, Rouphael N, Widge A, Jackson L, Roberts P, Makhene M . Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020; 383(25):2427-2438. PMC: 7556339. DOI: 10.1056/NEJMoa2028436. View

Ho H, Cunningham-Rundles C . Non-infectious Complications of Common Variable Immunodeficiency: Updated Clinical Spectrum, Sequelae, and Insights to Pathogenesis. Front Immunol. 2020; 11:149. PMC: 7025475. DOI: 10.3389/fimmu.2020.00149. View

Buckland M, Galloway J, Nic Fhogartaigh C, Meredith L, Provine N, Bloor S . Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nat Commun. 2020; 11(1):6385. PMC: 7736571. DOI: 10.1038/s41467-020-19761-2. View

van Vollenhoven R, Emery P, Bingham 3rd C, Keystone E, Fleischmann R, Furst D . Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010; 37(3):558-67. DOI: 10.3899/jrheum.090856. View

10.

Kos I, Balensiefer B, Roth S, Ahlgrimm M, Sester M, Schmidt T . Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab. Front Oncol. 2020; 10:1578. PMC: 7493633. DOI: 10.3389/fonc.2020.01578. View

11.

Robbiani D, Gaebler C, Muecksch F, Lorenzi J, Wang Z, Cho A . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020; 584(7821):437-442. PMC: 7442695. DOI: 10.1038/s41586-020-2456-9. View

12.

Fallet B, Kyburz D, Walker U . Mild Course of COVID-19 and Spontaneous Virus Clearance in a Patient With Depleted Peripheral Blood B Cells Due to Rituximab Treatment. Arthritis Rheumatol. 2020; 72(9):1581-1582. PMC: 7283641. DOI: 10.1002/art.41380. View

13.

Meca-Lallana V, Aguirre C, Beatrizdel Rio , Cardenoso L, Alarcon T, Vivancos J . COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies. Mult Scler Relat Disord. 2020; 44:102306. PMC: 7295509. DOI: 10.1016/j.msard.2020.102306. View

14.

Lucchini M, Bianco A, Del Giacomo P, De Fino C, Nociti V, Mirabella M . Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report. Mult Scler Relat Disord. 2020; 44:102323. PMC: 7307994. DOI: 10.1016/j.msard.2020.102323. View

15.

Calabrese L, Calabrese C, Lenfant T, Kirchner E, Strand V . Infections in the Era of Targeted Therapies: Mapping the Road Ahead. Front Med (Lausanne). 2020; 7:336. PMC: 7461856. DOI: 10.3389/fmed.2020.00336. View

16.

Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

17.

Assaad S, Avrillon V, Fournier M, Mastroianni B, Russias B, Swalduz A . High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR. Eur J Cancer. 2020; 135:251-259. PMC: 7275994. DOI: 10.1016/j.ejca.2020.05.028. View

18.

Sahraian M, Azimi A, Navardi S, Ala S, Naser Moghadasi A . Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord. 2020; 46:102472. PMC: 7456295. DOI: 10.1016/j.msard.2020.102472. View

19.

Ciotti J, Valtcheva M, Cross A . Effects of MS disease-modifying therapies on responses to vaccinations: A review. Mult Scler Relat Disord. 2020; 45:102439. PMC: 7395588. DOI: 10.1016/j.msard.2020.102439. View

20.

Corbett K, Flynn B, Foulds K, Francica J, Boyoglu-Barnum S, Werner A . Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020; 383(16):1544-1555. PMC: 7449230. DOI: 10.1056/NEJMoa2024671. View